Hengrui Medicine (600276.SH): SHR-2173 injection obtained approval for clinical trials of the drug.

China Fortune Finance and Economics APP News, Hengrui Medicine (600276.SH) announced that recently, its subsidiary Guangdong Hengrui Medicine Co., Ltd. received the approval notification letter for the drug clinical trial of SHR-2173 injection issued by the National Medical Products Administration (referred to as "NMPA"). The company will conduct clinical trials in the near future.